Decoy Therapeutics secured approximately $3.5 million through a private investment in public equity (PIPE) deal with a healthcare-focused institutional investor. The funds will support advancing its lead antiviral candidate into clinical trials targeting multiple respiratory viruses. The PIPE includes potential milestone-based warrants that could raise an additional $17.5 million if certain clinical and regulatory milestones are met. The company plans to close the offering around June 29, 2026, and aims to accelerate development using its AI-assisted IMP(3)ACT platform for broad antiviral treatments.
SpaceX's 2026 IPO on Nasdaq under the ticker SPCX has established a public market benchmark for the space launch economy, prompting investors to seek other investable companies in the sector. Rocket Lab Corporation (Nasdaq: RKLB) stands out with reco...
Ryanair has reversed its policy of charging parents a fee to sit next to their children after the UK's Competition and Markets Authority (CMA) launched an investigation into the practice. Previously, parents paid about $10.70 each way per adult to re...
Ethereum is trading around its critical 200-day moving average near $1,668, a level historically marking the divide between bull and bear markets. Despite record-strong fundamentals like high staking levels, large institutional inflows, and corporate...
The Trump administration has eased restrictions on Anthropic's AI model Mythos 5, permitting its use by over 100 US government agencies and companies, including access for non-American employees at these organizations. This follows a two-week ban aft...
Telo Genomics Corp. has terminated its investor relations consulting agreement with Sheridan Adams, LLC, effective June 12, 2026. The role was always intended to be temporary, and the company has expressed well wishes for Sheridan's future. Telo Geno...
